Perhaps the report on China’s strategy for eclipsing the U.S. lead in biopharma from the Information Technology & Innovation Foundation (ITIF) resonated so strongly with me because of several articles in The Wall Street Journal. Taken together, they present a sobering picture of what we’re up against.
{iframe}https://www.ipwatchdog.com/2019/08/15/the-dragon-targets-us-biopharma-lead/id=112230/{/iframe}